Cargando…

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Background. Adalimumab is effective for the maintenance of remission in patients with moderate-to-severe ulcerative colitis (UC). Currently, biologic therapies are used in cases where patients fail conventional medical therapies. If biologic therapies are not available, patients often choose to rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beilman, Candace L., Thanh, Nguyen Xuan, Ung, Victoria, Ma, Christopher, Wong, Karen, Kroeker, Karen I., Lee, Thomas, Wang, Haili, Ohinmaa, Arto, Jacobs, Phil, Halloran, Brendan P., Fedorak, Richard N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065999/ https://www.ncbi.nlm.nih.gov/pubmed/27781203 http://dx.doi.org/10.1155/2016/5315798

Ejemplares similares

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study
por: Ma, Christopher, et al.
Publicado: (2016)

Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature
por: Verma, Sanam, et al.
Publicado: (2013)

Polysomnography shows sleep fragmentation in patients with inactive inflammatory bowel disease
por: Beilman, Candace, et al.
Publicado: (2020)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study
por: Keshteli, Ammar Hassanzadeh, et al.
Publicado: (2017)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013)

Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection
por: Lee, Jin-Hyup, et al.
Publicado: (2017)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
por: Wessman, Laurel L., et al.
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Anti-Inflammatory Diet Prevents Subclinical Colonic Inflammation and Alters Metabolomic Profile of Ulcerative Colitis Patients in Clinical Remission
por: Keshteli, Ammar Hassanzadeh, et al.
Publicado: (2022)

The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta
por: Akpinar, Ilke, et al.
Publicado: (2019)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Kim, Jae Hyun, et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
por: Hoffmann, Sebastian, et al.
Publicado: (2018)

Reversible Corpus Callosal Lesions Associated with the Use of Adalimumab for Ulcerative Colitis
por: Park, Jin-Woo, et al.
Publicado: (2017)

A57 ULCERATIVE COLITIS DISEASE ACTIVITY IS DOMINATED BY INNATE IMMUNITY AND FEATURES OF TISSUE REMODELING
por: Madill-Thomsen, K, et al.
Publicado: (2022)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Okabayashi, Shinji, et al.
Publicado: (2017)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab
por: Alshehri, Hamza, et al.
Publicado: (2023)

A160 MOLECULAR ANALYSIS OF THE INJURY-REPAIR RESPONSE IN ULCERATIVE COLITIS REVEALS HETEROGENEITY IN DISEASE ACTIVIT
por: Madill-Thomsen, K, et al.
Publicado: (2022)

Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis
por: Rispo, Antonio, et al.
Publicado: (2016)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring
por: Wasserbauer, Martin, et al.
Publicado: (2022)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients
por: Tran, Bach Xuan, et al.
Publicado: (2012)

Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature
por: LaConti, Joseph J., et al.
Publicado: (2016)

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
por: Park, Sang Hyoung, et al.
Publicado: (2022)

Neurotuberculosis in a Patient with Ulcerative Colitis Using Long-Term Adalimumab: A Rare Case
por: Facanali, Carolina Bortolozzo Graciolli, et al.
Publicado: (2023)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
por: Numa, Keijiro, et al.
Publicado: (2023)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
por: Schultz, Bob G, et al.
Publicado: (2021)

A204 COST-EFFECTIVENESS OF THERAPIES AFTER FAILURE OF CONVENTIONAL THERAPY FOR PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THE CANADIAN HEALTHCARE SYSTEM
por: Hagerman, C, et al.
Publicado: (2023)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis
por: Sakurai, Toshiharu, et al.
Publicado: (2020)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

Vogt–Koyanagi–Harada Disease and Systemic Lupus Erythematosus Occurring during Adalimumab Therapy for Ulcerative Colitis
por: AlBloushi, Abdulrahman F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gu4qgusgh0sr9fm4acjbjau7qg